Moore RD - Search Results

1

Clostridium difficile in a HIV-infected cohort: incidence, risk factors, and clinical outcomes.

Haines CF, Moore RD, Bartlett JG, Sears CL, Cosgrove SE, Carroll K, Gebo KA. Haines CF, et al. Among authors: moore rd. AIDS. 2013 Nov 13;27(17):2799-807. doi: 10.1097/01.aids.0000432450.37863.e9. AIDS. 2013. PMID: 23842125 Free PMC article.

2

A comprehensive plan for managed care of patients infected with human immunodeficiency virus.

Bartlett JG, Moore R. Bartlett JG, et al. Clin Infect Dis. 1999 Jul;29(1):50-5. doi: 10.1086/520179. Clin Infect Dis. 1999. PMID: 10433564

3

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Sulkowski MS, et al. Among authors: moore rd. JAMA. 2002 Jul 10;288(2):199-206. doi: 10.1001/jama.288.2.199. JAMA. 2002. PMID: 12095384

4

Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.

Gebo KA, Keruly J, Moore RD. Gebo KA, et al. Among authors: moore rd. J Gen Intern Med. 2003 Feb;18(2):104-11. doi: 10.1046/j.1525-1497.2003.10801.x. J Gen Intern Med. 2003. PMID: 12542584 Free PMC article.

5

Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings.

Spacek LA, Griswold M, Quinn TC, Moore RD. Spacek LA, et al. Among authors: moore rd. AIDS. 2003 Jun 13;17(9):1311-7. doi: 10.1097/00002030-200306130-00005. AIDS. 2003. PMID: 12799552

6

The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons.

Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. Mehta SH, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):577-84. doi: 10.1097/00126334-200308150-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12902801

7

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. doi: 10.1097/00126334-200310010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 14526205

8

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: moore rd. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

9

Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.

Moore RD, Keruly JC, Chaisson RE. Moore RD, et al. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):46-51. doi: 10.1097/00126334-200401010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 14707791

10

The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV.

Gebo KA, Moore RD, Fleishman JA. Gebo KA, et al. Among authors: moore rd. Hopkins HIV Rep. 2003 Nov;15(6):5-6. Hopkins HIV Rep. 2003. PMID: 14974424 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

930 results

Search Page

Filters